STOCK TITAN

Unicycive Therapeutics, Inc. - UNCY STOCK NEWS

Welcome to our dedicated page for Unicycive Therapeutics news (Ticker: UNCY), a resource for investors and traders seeking the latest updates and insights on Unicycive Therapeutics stock.

Unicycive Therapeutics, Inc. (NASDAQ: UNCY) is a biotechnology company committed to developing innovative treatments for kidney diseases with significant unmet medical needs. The company's primary focus lies in addressing hyperphosphatemia and acute kidney injury (AKI) through its advanced drug candidates: Renazorb and UNI-494.

Renazorb is a novel phosphate-binding agent under development for the treatment of hyperphosphatemia. Utilizing proprietary nanoparticle technology, Renazorb aims to reduce the pill burden for patients, thereby promising better adherence and compliance. Hyperphosphatemia, a common condition in patients with End Stage Renal Disease (ESRD), if left untreated, can lead to severe complications such as secondary hyperparathyroidism, renal osteodystrophy, and cardiovascular diseases. Despite the availability of several FDA-approved treatments, around 75% of U.S. dialysis patients fail to achieve target phosphorus levels. Renazorb has the potential to capture a significant share of the market, which exceeds $2.5 billion globally.

UNI-494 is another promising candidate, a novel nicotinamide ester derivative designed for the treatment of AKI. UNI-494 works by restoring mitochondrial function, a critical factor in kidney health. The drug is currently in Phase 1 dose-ranging safety studies in the United Kingdom, with completion expected in the second half of 2024. UNI-494 has been granted orphan drug designation by the U.S. FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients. DGF is a serious complication following kidney transplantation, often requiring dialysis intervention during the first week post-transplant.

Unicycive recently received significant financial backing from leading healthcare investors, including Octagon Capital and Great Point Partners, LLC., in addition to support from existing investors like Logos Capital and Nantahala Capital. This funding will likely support the company's ongoing research and development efforts.

For the latest updates, Unicycive expects topline data from its clinical studies by the second quarter of 2024. This progress underscores Unicycive's commitment to delivering groundbreaking treatments for kidney disease patients worldwide.

For investor inquiries, please contact: ir@unicycive.com or call (650) 543-5470.

Rhea-AI Summary

Unicycive Therapeutics has entered a partnership with Lee's Pharmaceutical to develop and market Renazorb® for hyperphosphatemia in patients with chronic kidney disease across Asia, including China. Unicycive will receive a $1 million upfront payment, potential milestone payments, and tiered royalties based on sales performance. The agreement capitalizes on Lee’s Pharm’s expertise in the region, where the renal disease market is expanding due to rising chronic kidney disease rates. Renazorb is designed to improve patient compliance by reducing pill burden, a critical factor for effective treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.74%
Tags
none
-
Rhea-AI Summary

Unicycive Therapeutics, a clinical-stage biotechnology company focused on kidney disease therapies, will present at the JMP Securities Life Sciences Conference on June 16, 2022, at 10:30 am ET. CEO Shalabh Gupta will showcase the company’s innovative treatments, including its lead drug Renazorb for hyperphosphatemia and the new entity UNI-494 for acute kidney injury. The event will be held in New York City, and the presentation will be available via live webcast on the company’s website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.9%
Tags
conferences
-
Rhea-AI Summary

Unicycive Therapeutics has initiated a pivotal clinical bioequivalence study for Renazorb, a phosphate binding agent, to treat hyperphosphatemia in patients with kidney disease. This single study, approved by the FDA, aims to demonstrate pharmacological efficacy compared to Fosrenol. The study will enroll 64 participants and evaluate urinary phosphate excretion changes. Previous trials showed Renazorb was safe and effective at reducing urine phosphate, addressing a significant unmet need in a market exceeding $1 billion. Unicycive is also preparing for commercialization.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.14%
Tags
none
Rhea-AI Summary

Unicycive Therapeutics (Nasdaq: UNCY) reported its financial results for Q1 2022, revealing a net loss of $3.5 million ($0.24 per share), up from $1.0 million ($0.11 per share) in Q1 2021. Research and development expenses rose to $1.9 million, mainly due to ongoing drug development for Renazorb and UNI-494. The company is set to begin a bioequivalence study for Renazorb in Q2 2022 and anticipates filing a 505(b)(2) NDA. With $13.6 million in cash, Unicycive is adequately funded for upcoming milestones, including the clinical trial for UNI-494 planned for later in 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.78%
Tags
-
Rhea-AI Summary

Unicycive Therapeutics (Nasdaq: UNCY) announced a Key Opinion Leader (KOL) Event featuring Dr. Glenn Chertow from Stanford University on April 20, 2022. The event, titled “Novel Treatments in Kidney Disease,” aims to discuss innovative therapies for kidney disease, particularly hyperphosphatemia affecting over 500,000 chronic kidney disease patients in the U.S. Unicycive is developing Renazorb, a phosphate binder, and a pro-drug of nicorandil for treating both acute and chronic kidney conditions. The live webcast will be available for 90 days post-event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.88%
Tags
none
-
Rhea-AI Summary

Unicycive Therapeutics (Nasdaq: UNCY) reported its financial results for 2021, highlighting significant progress in clinical development. The FDA confirmed a regulatory pathway for its lead product, Renazorb, aimed at treating hyperphosphatemia in chronic kidney disease patients. The company plans to initiate a clinical bioequivalence study in healthy volunteers in Q2 2022. R&D expenses rose to $6.1 million from $1.0 million in 2020, while the net loss increased to $10.0 million, or $0.86 per share. Cash and equivalents stood at $16.6 million as of December 31, 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.27%
Tags
Rhea-AI Summary

Unicycive Therapeutics will celebrate National Kidney Month by ringing the Nasdaq Closing Bell on March 29, 2022, at 4:00 PM ET. The event, featuring CEO Shalabh Gupta, highlights the unmet medical needs for kidney disease treatments. Unicycive is progressing towards regulatory approval for its lead drug, Renazorb, aimed at treating hyperphosphatemia, and plans to file for UNI-494 targeting acute kidney injury later in the year. The Nasdaq listing has enhanced liquidity and visibility among institutional investors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.58%
Tags
none
-
Rhea-AI Summary

Unicycive Therapeutics (Nasdaq: UNCY) has announced that Dr. Shalabh Gupta, CEO, will present at two investor conferences in March 2022. The first is the 34th Annual ROTH Conference from March 13-15, where Dr. Gupta will offer an online presentation and participate in one-on-one meetings. The second event is the Maxim Group 2nd Annual Virtual Growth Conference on March 28 at 1:00 pm Eastern Time, featuring a fireside chat format. Unicycive is focused on developing innovative therapies for kidney diseases, including its lead drug Renazorb.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.14%
Tags
conferences
-
Rhea-AI Summary

Unicycive Therapeutics (Nasdaq: UNCY) announced that two abstracts highlighting the efficacy and safety of Renazorb (lanthanum dioxycarbonate) will be presented at the National Kidney Foundation (NKF) Spring Clinical Meeting from April 6-10, 2022, in Boston. Renazorb aims to treat hyperphosphatemia in chronic kidney disease patients, utilizing advanced nanoparticle technology for better phosphate binding. The data presented will support Renazorb's potential as a leading phosphate binder with fewer dosage pills required.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.57%
Tags
Rhea-AI Summary

Unicycive Therapeutics, a clinical stage biotechnology company focused on kidney disease therapies, announced that CEO Shalabh Gupta will present at the H.C. Wainwright BIOCONNECT Virtual Conference from January 10-13, 2022. The presentation can be accessed on the company's website under the Investors section starting January 10, 2022, at 7:00 a.m. ET. Unicycive is developing innovative treatments, including Renazorb, a phosphate binding agent for hyperphosphatemia, and UNI-494, a new chemical entity in late preclinical development for acute kidney injury.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.17%
Tags
conferences

FAQ

What is the current stock price of Unicycive Therapeutics (UNCY)?

The current stock price of Unicycive Therapeutics (UNCY) is $0.684 as of December 20, 2024.

What is the market cap of Unicycive Therapeutics (UNCY)?

The market cap of Unicycive Therapeutics (UNCY) is approximately 75.8M.

What is Unicycive Therapeutics, Inc.?

Unicycive Therapeutics, Inc. is a biotechnology company focused on developing treatments for kidney diseases with significant unmet medical needs.

What is Renazorb?

Renazorb is a novel phosphate-binding agent being developed by Unicycive for the treatment of hyperphosphatemia.

What is UNI-494?

UNI-494 is a new chemical entity with a novel mechanism of action aimed at treating acute kidney injury. It is currently in Phase 1 clinical trials.

What are hyperphosphatemia and its complications?

Hyperphosphatemia is a condition of elevated phosphate levels in the blood, common in ESRD patients. It can lead to complications like secondary hyperparathyroidism, renal osteodystrophy, and cardiovascular diseases.

What is Delayed Graft Function (DGF)?

DGF is an acute kidney injury occurring within the first week post-kidney transplantation, often requiring dialysis. It can lead to impaired graft function and higher rates of tissue rejection.

What is the market opportunity for Renazorb?

The global market opportunity for treating hyperphosphatemia is projected to exceed $2.5 billion in 2023, with the U.S. accounting for over $1 billion.

Who are the major investors in Unicycive?

Leading investors include Octagon Capital, Great Point Partners, LLC, Logos Capital, and Nantahala Capital.

When will the topline data be available?

Topline data from Unicycive's clinical studies are expected in the second quarter of 2024.

How can I contact Unicycive for investor inquiries?

You can contact Unicycive at ir@unicycive.com or call (650) 543-5470 for investor inquiries.

What is the significance of UNI-494's orphan drug designation?

The orphan drug designation by the U.S. FDA allows UNI-494 to receive benefits like market exclusivity, grants, and tax credits for its development aimed at treating rare conditions like Delayed Graft Function.

Unicycive Therapeutics, Inc.

Nasdaq:UNCY

UNCY Rankings

UNCY Stock Data

75.75M
97.44M
6.73%
38.24%
1.12%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
LOS ALTOS